Open Board Meeting
Questions and answers
I’ve heard about people that have survived COVID-19 being able to donate their plasma to help others battling the disease. Is Canadian Blood Services involved in that?
Convalescent plasma is plasma that is collected from patients who have recovered from a virus, which means they have developed the antibodies necessary to fight off that virus. These antibodies develop in the body’s plasma and remain there — even after someone has fully recovered — to shield them from possible future infection from that virus.
In theory, these antibodies could be the key ingredient for a treatment to help others with the same virus.
We are proud to be part of CONCOR, a national clinical trial to test the safety and effectiveness of COVID-19 convalescent plasma as a possible treatment option for patients with the virus.
With Health Canada’s approval of our clinical trial application, Canadian Blood Services and Héma-Québec are responsible for supplying convalescent plasma to Canadian physicians caring for patients with the virus in the context of the clinical trial. As the national blood operator, we have the expertise and the infrastructure necessary to safely collect, prepare and distribute convalescent plasma for use in a trial of this size and scope.
While I understand that pins, certificates and plastic donor cards are handed out based on the number of donor visits, would you ever consider adding to the rewards program a criteria for tracking the total amount of blood donated?
Over the last several months Canadian Blood Services has procured the help of our research experts at IPSOS to garner insights from new, existing and potential blood and plasma donors on how to evolve the donor recognition program. Our donor recognition program will continue to be built with the input of our donors. Recommendations on how to evolve the program will be reviewed in the fall of 2020.